Fibroblast growth factor 21 is a hepatokine involved in MASLD progression
United European Gastroenterology Journal
by Rocío Gallego‐Durán, Javier Ampuero, Douglas Maya‐Miles, Helena Pastor‐Ramírez, Rocío Montero‐Vallejo, Jesús Rivera‐Esteban, Leticia Álvarez‐Amor, María Jesús Pareja, María Carmen Rico, Raquel Millán, María José Robles‐Frías, Rocío Aller, Ángela Rojas, Rocío Muñoz‐Hernández, Antonio Gil‐Gómez, Sheila Gato, María García‐Lozano, María Teresa Arias‐Loste, Javier Abad, José Luis Calleja, Raúl J. Andrade, Javier Crespo, Águeda González‐Rodríguez, Carmelo García‐Monzón, Fausto Andreola, Juan Manuel Pericás, Rajiv Jalan, Francisco Martín‐Bermudo, Manuel Romero‐Gómez
19h ago
Abstract Aim We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level. Methods We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte-derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high-fat and choline-deficient diet (CDA-HFD) for 16 weeks to assess hepatic FGF21 protein expr ..read more
Visit website
Wake up and smell the coffee: The potential of faecal volatile organic compounds in paediatric inflammatory bowel disease
United European Gastroenterology Journal
by Eva Vermeer, Nanne K. H. de Boer, Tim G. J. de Meij
19h ago
United European Gastroenterology Journal, EarlyView ..read more
Visit website
Culture‐based susceptibility‐guided tailored versus empirical concomitant therapy as first‐line Helicobacter pylori treatment: A randomized clinical trial
United European Gastroenterology Journal
by Jeong Hoon Lee, Byung‐Hoon Min, Eun Jeong Gong, Jun Young Kim, Hee Kyong Na, Ji Yong Ahn, Do Hoon Kim, Kee Don Choi, Yang Won Min, Hyuk Lee, Jun Haeng Lee, Hwoon‐Yong Jung, Jae J. Kim
19h ago
Abstract Background With the increasing resistance to antimicrobial agents, susceptibility-guided tailored therapy has been emerging as an ideal strategy for Helicobacter pylori treatment. However, susceptibility-guided tailored therapy requires additional cost, time consumption, and invasive procedure (endoscopy) and its superiority over empirical quadruple therapy as the first-line H. pylori treatment remains unclear. Aims To compare the efficacy of culture-based susceptibility-guided tailored versus empirical concomitant therapy as the first-line Helicobacter pylori treatment. Methods This ..read more
Visit website
Peroral endoscopic myotomy for hypercontractile (Jackhammer) esophagus: A retrospective multicenter series with long‐term follow‐up
United European Gastroenterology Journal
by David Albers, Mana Witt, John E. Pandolfino, Thomas Rösch, Guido Schachschal, Torsten Beyna, Horst Neuhaus, Christian Gerges, Jennis Kandler, Hans‐Dieter Allescher, Jan Martinek, Alessandro Repici, Alanna Ebigbo, Helmut Messmann, Brigitte Schumacher, Yuki B. Werner
4d ago
Abstract Introduction Long-term outcome data are limited for non-achalasia esophageal motility disorders treated by peroral endoscopy myotomy (POEM) as a separate group. We investigated a subset of symptomatic patients with hypercontractile esophagus (Jackhammer esophagus). Methods Forty two patients (mean age 60.9 years; 57% female, mean Eckardt score 6.2 ± 2.1) treated by primary peroral myotomy for symptomatic Jackhammer esophagus 2012–2018 in seven European centers were retrospectively analyzed; myotomy included the lower esophageal sphincter but did not extend more than 1 ..read more
Visit website
Expert assessment of infiltration depth and recommendation of endoscopic resection technique in early Barrett cancer
United European Gastroenterology Journal
by Fadi Younis, Thomas Rösch, Torsten Beyna, Alanna Ebigbo, Siegbert Faiss, Andrea May, Oliver Pech, Philip Dautel, Mario Anders, Till Clauditz, Katharina Zimmermann‐Fraedrich, Susanne Sehner, Guido Schachschal
4d ago
Abstract Background Early Barrett cancer can be curatively treated by endoscopic resection. The choice of the resection technique, however—endoscopic mucosal resection (EMR) or submucosal dissection (ESD)—largely depends on the assumed infiltration depth as judged by the endoscopist. However, the accuracy of endoscopic diagnosis of the degree of cancer infiltration is not known. Methods Three to four high-quality images (both in overview and close-up) from 202 of early Barrett esophagus cancer cases (82% men, mean age 66.9 years) were selected from our endoscopy database (73.3% stage T1a ..read more
Visit website
Issue Information
United European Gastroenterology Journal
by
4d ago
No abstract is available for this article ..read more
Visit website
Advancing patient‐centered care: Recent developments in UEG's patient relations
United European Gastroenterology Journal
by Patrizia Burra, Jorge Amil Dias, Joana Torres, Andreea Botos, Pilar Acedo, Benthe Bertelsen, Michael Bretthauer, Anna Carboni, Ana Dugic, Pierluigi Fracasso, Tunde Koltai, Salvatore Leone, Zorana Maravic, Tamara Matysiak‐Budnik, Lone McColaugh, Milan Mishkovikj, Kremlin Wickramasinghe, Monique van Leerdam
1w ago
..read more
Visit website
Quality of clinical guidelines: It matters as it impacts patient care
United European Gastroenterology Journal
by Iris J. M. Levink, Alberto Balduzzi, Irene Marafini, Haluk Tarik Kani, Yasuko Maeda, on behalf of the UEGJ Guideline Taskforce
2w ago
United European Gastroenterology Journal, EarlyView ..read more
Visit website
Shedding a new light on gastric cancer screening
United European Gastroenterology Journal
by Anthea Pisani, Diogo Libânio, Lumír Kunovský
3w ago
United European Gastroenterology Journal, EarlyView ..read more
Visit website
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
United European Gastroenterology Journal
by Julian Panés, Geert R. D’Haens, Bruce E. Sands, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Séverine Vermeire
1M ago
Abstract Background and Aims Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report an integrated summary of tofacitinib safety from the completed global UC clinical program (9.2 years maximum tofacitinib exposure). Methods This analysis included patients receiving tofacitinib 5 or 10 mg twice daily (b.i.d.) from completed phase 2/3 placebo-controlled studies, an open-label, long-term extension study and a randomized phase 3b/4 study. Proportions and incidence rates (IRs; unique patients with events/100 patient-years [PY] of exposure) w ..read more
Visit website

Follow United European Gastroenterology Journal on FeedSpot

Continue with Google
Continue with Apple
OR